It seldom reads like the King’s English, but patent language can be the written difference between a successful company’s [MORE]
Several bills now in Congress could result in a fundamental change to patenting biologics (such as monoclonal antibodies). One bill [MORE]
In September, the President’s Council of Advisors on Science and Technology published its report “Priorities for Personalized Medicine.” It reviews [MORE]